Literature DB >> 7486918

Antagonistic interactions between azoles and amphotericin B with yeasts depend on azole lipophilia for special test conditions in vitro.

M Scheven1, F Schwegler.   

Abstract

The interactions of the azole antifungal agents fluconazole, itraconazole, ketoconazole, or miconazole with amphotericin B (AmB) in their effect on Candida albicans were investigated. These four azoles antagonized the fungistatic activity of AmB at sub-MICs if both substances acted simultaneously. This coincubation test was primarily developed to observe the azole-mediated demethylase inhibition quantitatively by bioassay. Interestingly, the occurrence of azole-AmB antagonism depended on azole lipophilia if specially selected test conditions were applied. By a consecutive incubation regimen, preincubation at high azole concentrations (1 to 50 micrograms/ml) and then subsequent incubation with AmB (1 microgram/ml), only preincubation with the three lipophilic azoles decreased the fungicidal activity of AmB but not that of FCZ. It was shown that yeasts absorb only lipophilic azoles to a remarkable extent. This fact might be responsible for the absence of antagonism of FCZ to AmB when yeasts were incubated consecutively. It can be concluded with caution that consecutive treatment of candidiasis with FCZ and AmB does not necessarily result in a clinically relevant antagonism.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7486918      PMCID: PMC162825          DOI: 10.1128/AAC.39.8.1779

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Combination therapy for systemic mycosis.

Authors:  A Polak
Journal:  Infection       Date:  1989 Jul-Aug       Impact factor: 3.553

2.  In vitro synergy and antagonism of antifungal agents against yeast-like fungi.

Authors:  B Dupont; E Drouhet
Journal:  Postgrad Med J       Date:  1979-09       Impact factor: 2.401

3.  Azole resistance in Candida albicans.

Authors:  J F Ryley; R G Wilson; K J Barrett-Bee
Journal:  Sabouraudia       Date:  1984

4.  Inhibition of potentially pathogenic yeastlike fungi by clotrimazole in combination with 5-fluorocytosine or amphotericin B.

Authors:  W H Beggs; G A Sarosi; N M Steele
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

5.  Effect of ketoconazole on the fungicidal action of amphotericin B in Candida albicans.

Authors:  I J Sud; D S Feingold
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

6.  Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro.

Authors:  F C Odds
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

7.  Antifungal action of amphotericin B in combination with other polyene or imidazole antibiotics.

Authors:  J Brajtburg; D Kobayashi; G Medoff; G S Kobayashi
Journal:  J Infect Dis       Date:  1982-08       Impact factor: 5.226

8.  The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis.

Authors:  A Schaffner; P G Frick
Journal:  J Infect Dis       Date:  1985-05       Impact factor: 5.226

9.  Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients. Bone Marrow Transplantation Team.

Authors:  P H Chandrasekar; C M Gatny
Journal:  Chemotherapy       Date:  1994 Mar-Apr       Impact factor: 2.544

Review 10.  Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action.

Authors:  H Vanden Bossche
Journal:  Curr Top Med Mycol       Date:  1985
View more
  16 in total

Review 1.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

2.  Voriconazole-induced inhibition of the fungicidal activity of amphotericin B in Candida strains with reduced susceptibility to voriconazole: an effect not predicted by the MIC value alone.

Authors:  Anders Lignell; Elisabeth Löwdin; Otto Cars; Dominique Sanglard; Jan Sjölin
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

3.  SAR Studies on Aromatic Acylhydrazone-Based Inhibitors of Fungal Sphingolipid Synthesis as Next-Generation Antifungal Agents.

Authors:  Krupanandan Haranahalli; Cristina Lazzarini; Yi Sun; Julia Zambito; Senuri Pathiranage; J Brian McCarthy; John Mallamo; Maurizio Del Poeta; Iwao Ojima
Journal:  J Med Chem       Date:  2019-08-16       Impact factor: 7.446

4.  Combination antifungal therapy for invasive pulmonary aspergillosis.

Authors:  Salman Abdulaziz; Hamdan Al Jahdali; Salim Baharoon
Journal:  BMJ Case Rep       Date:  2012-12-14

5.  Interactions of posaconazole and flucytosine against Cryptococcus neoformans.

Authors:  F Barchiesi; A M Schimizzi; L K Najvar; R Bocanegra; F Caselli; S Di Cesare; D Giannini; L F Di Francesco; A Giacometti; F Carle; G Scalise; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

6.  Interactions between triazoles and amphotericin B against Cryptococcus neoformans.

Authors:  F Barchiesi; A M Schimizzi; F Caselli; A Novelli; S Fallani; D Giannini; D Arzeni; S Di Cesare; L F Di Francesco; M Fortuna; A Giacometti; F Carle; T Mazzei; G Scalise
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

7.  Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model.

Authors:  Joseph Meletiadis; Theodouli Stergiopoulou; Elizabeth M O'Shaughnessy; Joanne Peter; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2007-03-26       Impact factor: 5.191

8.  Stable phenotypic resistance of Candida species to amphotericin B conferred by preexposure to subinhibitory levels of azoles.

Authors:  J A Vazquez; M T Arganoza; D Boikov; S Yoon; J D Sobel; R A Akins
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

9.  Comparative pharmacodynamic interaction analysis of triple combinations of caspofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B against Aspergillus spp.

Authors:  Joanne P Demchok; Joseph Meletiadis; Emmanuel Roilides; Thomas J Walsh
Journal:  Mycoses       Date:  2009-03-07       Impact factor: 4.377

Review 10.  Invasive oesophageal candidiasis: current and developing treatment options.

Authors:  Jose A Vazquez
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.